ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
ERYTECHAnnounces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
Cambridge, MA (U.S.) and Lyon (France), May 24, 2023– ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 23, 2023.
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 23, 2023 at 09:30am CEST at the Hôtel Intercontinental, 2 rue Scribe, 75009 Paris (FRANCE).
Shareholders may participate in the General Meeting as follows:
- Attend in person;
- Voting by mail or by internet on the secure voting platform Votaccess; or
- Give a proxy to any individual or legal entity of their choice, under the applicable legal and regulatory conditions, or give a proxy to the Chairman of the Shareholders' Meeting. The Chairman will then vote on their behalf in favor of the adoption of the draft resolutions presented or approved by the Board of Directors and against the adoption of all other draft resolutions.
Availability of the documents for the Shareholders’ Meeting
The notice of meeting including the agenda and the draft resolutions, together with the principal details for attending and voting at the Combined Shareholders’ Meeting was published in the French Bulletin of Legal Announcements no. 59 on May 17, 2023.
Shareholders have access to the preparatory and information documents for the Shareholders’ Meeting as provided for by law and the regulations. They may also be viewed on the Company website at: https://investors.erytech.com/general-meeting. Shareholders are kindly advised to consult this section on a regular basis, as it may be updated to specify the final terms and conditions of participation in this Shareholders’ Meeting, in accordance with legal and regulatory requirements.
About ERYTECH: www.erytech.com
ERYTECH is a biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.
On February 15 2023, ERYTECH announced its intended strategic combination with PHERECYDES to create a global player in extended phage. More detail can be found in the press release.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com
CONTACTS
| ERYTECH Eric Soyer CFO & COO | NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com | +33 1 44 71 94 94 erytech@newcap.eu |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Equinor ASA: Share buy-back6.6.2023 08:00:00 CEST | Press release
Please see below information about transactions made under the share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the second tranche of the share buy-back programme for 2023 was announced: 4 May 2023. The duration of the second tranche of the buy-back programme for 2023: 11 May to no later than 25 July 2023. Size of the buy-back programme: Up to 94,000,000 shares, with a maximum total consideration for the second tranche: USD 550,000,000. From 29 May to 2 June, Equinor ASA has purchased a total of 2,117,395 own shares at the Oslo Stock Exchange at an average price of NOK 288.2593 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)29 May30 May510,000292.4021149,125,071.0031 May560,000284.7080159,436,480.001 June550,000284.5167156,484,185.002 June497,395292.1483145,313,103.68Previously disclosed buy-backs under the second tranche of the 2023 programme 4,0
Progress on share buyback programme6.6.2023 08:00:00 CEST | Press release
Progress on share buyback programme ING announced today that, in line with the launch of our €1.5 billion share buyback programme announced on 11 May 2023, we repurchased 1,711,037 shares during the week of 29 May 2023 up to and including 2 June 2023. The shares were repurchased at an average price of €11.81 for a total amount of €20,199,121.24. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at www.ing.com/investorrelations. The total number of shares repurchased under this programme to date is 5,466,433 ordinary shares at an average price of €11.91 for a total consideration of €65,084,362.50. To date approximately 4.34% of the maximum total value of the share buyback programme has been completed. Note for editors For further information on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom or via the @ING_news Twitter feed. Photos of ING operations, buildings and it
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference6.6.2023 08:00:00 CEST | Press release
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, 11:20 AM PDT on June 13, 2023 (2:20 PM EDT / 8:20 PM CEST). A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function
Sampo plc’s share buybacks 05/06/20236.6.2023 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 06/06/2023 at 08:30 am Sampo plc’s share buybacks 05/06/2023 On 05/06/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)7,94943.63AQEU31,84643.50CEUX13,65043.61TQEX66,55543.52XHELTOTAL120,00043.53 *rounded to two decimals On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is based on the authorisation granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 4,530,623 Sampo A shares representing 0.89 per cent of the total number of shares in Sampo plc. Details o
IDEX Biometrics – Disclosure of holding - 6 June 20236.6.2023 07:30:00 CEST | Press release
This notice is issued by IDEX Biometrics ASA on behalf of the shareholder mentioned below. Reference is made to the disclosure on 26 May that Robert Keith had lent 42,000,000 shares in connection with the settlement of Tranche 1 in the private placement of shares in IDEX Biometrics on 24 May 2023. The shares have been returned to Mr. Keith. After the return of the shares, Mr. Keith and close relations hold 157,873,873 shares or rights to shares or 12.3% of the total outstanding shares and votes in IDEX Biometrics, based on the share capital after completion of Tranche 1 of the private placement. This notice was published by Erling Svela, Vice president of finance, on 6 June 2023 at 07:30 CET on behalf of IDEX Biometrics ASA on behalf of Robert Keith.